Merck Raises FY2025 Adj EPS Guidance from $8.87-$8.97 to $8.93-$8.98 vs $8.91 Est; Narrows FY2025 Sales Guidance from $64.300B-$65.300B to $64.500B-$65.000B vs $64.662B Est

Author: Benzinga Newsdesk | October 30, 2025 05:32am

Full-Year 2025 Financial Outlook 

The following table summarizes the Company's full-year financial outlook.

	Full Year 2025
	Updated		Prior
Sales*	$64.5 billion to $65.0 billion		$64.3 billion to $65.3 billion
Non-GAAP Gross margin2	Approximately 82%		Approximately 82%
Non-GAAP Operating expenses2(a)	$25.9 billion to $26.4 billion		$25.6 billion to $26.4 billion
Non-GAAP Other (income) expenses, net2	$400 million to $500 million expense		$300 million to $400 million expense
Non-GAAP Effective tax rate2	14.0% to 15.0%		15.0% to 16.0%
Non-GAAP EPS2(b)(c)	$8.93 to $8.98		$8.87 to $8.97
Share count (assuming dilution)	Approximately 2.51 billion		Approximately 2.51 billion

Posted In: MRK